Stocks
Agios Pharmaceuticals Financial Statements (AGIO) |
||||||||||
| Agios Pharmaceuticalssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 03.08.2023 | 02.11.2023 | 15.02.2024 | 02.05.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 5.61 | 6.71 | 7.40 | 7.10 | 8.19 | 29.4 | |||
| Operating Income, bln rub | -90.6 | -93.7 | -100.9 | -106.3 | -92.1 | -392.9 | ||||
| EBITDA, bln rub | ? | -90.6 | -93.7 | -100.9 | -104.9 | -90.7 | -390.2 | |||
| Net profit, bln rub | ? | -71.4 | -83.8 | -91.3 | -95.9 | -81.5 | -352.6 | |||
| OCF, bln rub | ? | -95.2 | -66.7 | -61.6 | -72.5 | -99.9 | -300.7 | |||
| CAPEX, bln rub | ? | 0.399 | 0.003 | 17.9 | 0.234 | 0.141 | 18.2 | |||
| FCF, bln rub | ? | -95.6 | -66.7 | -79.5 | -72.7 | -100.0 | -319.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 95.7 | 99.3 | 107.7 | 111.4 | 98.3 | 416.6 | ||||
| Cost of production, bln rub | 0.554 | 1.11 | 0.633 | 1.99 | 1.98 | 5.71 | ||||
| R&D, bln rub | 67.3 | 68.9 | 81.8 | 76.1 | 67.3 | 294.1 | ||||
| Interest expenses, bln rub | 9.60 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Assets, bln rub | 1 151 | 1 085 | 1 007 | 937.1 | 849.7 | 849.7 | ||||
| Net Assets, bln rub | ? | 1 037 | 964.2 | 886.8 | 811.0 | 743.9 | 743.9 | |||
| Debt, bln rub | 82.3 | 78.9 | 75.5 | 72.0 | 68.3 | 68.3 | ||||
| Cash, bln rub | 1 011 | 946.9 | 872.4 | 776.9 | 598.0 | 598.0 | ||||
| Net debt, bln rub | -928.6 | -868.0 | -796.9 | -704.9 | -529.6 | -529.6 | ||||
| Ordinary share price, rub | 23.0 | 28.3 | 24.8 | 22.3 | 29.2 | 21.0 | ||||
| Number of ordinary shares, mln | 55.1 | 55.5 | 55.8 | 55.9 | 56.4 | 56.4 | ||||
| Market cap, bln rub | 1 266 | 1 572 | 1 381 | 1 245 | 1 649 | 1 183 | ||||
| EV, bln rub | ? | 337 | 704 | 584 | 540 | 1 119 | 654 | |||
| Book value, bln rub | 1 037 | 964 | 887 | 811 | 744 | 744 | ||||
| EPS, rub | ? | -1.30 | -1.51 | -1.64 | -1.72 | -1.45 | -6.25 | |||
| FCF/share, rub | -1.73 | -1.20 | -1.42 | -1.30 | -1.77 | -5.66 | ||||
| BV/share, rub | 18.8 | 17.4 | 15.9 | 14.5 | 13.2 | 13.2 | ||||
| EBITDA margin, % | ? | -1 615% | -1 396% | -1 364% | -1 476% | -1 108% | -1 327% | |||
| Net margin, % | ? | -1 273% | -1 249% | -1 234% | -1 351% | -995.8% | -1 199% | |||
| FCF yield, % | ? | -24.4% | -19.1% | -22.3% | -25.3% | -19.3% | -27.0% | |||
| ROE, % | ? | -5.55% | -5.75% | -8.38% | -42.2% | -47.4% | -47.4% | |||
| ROA, % | ? | -5.00% | -5.11% | -7.38% | -36.5% | -41.5% | -41.5% | |||
| P/E | ? | -22.0 | -28.4 | -18.6 | -3.63 | -4.68 | -3.36 | |||
| P/FCF | -4.09 | -5.24 | -4.48 | -3.96 | -5.17 | -3.71 | ||||
| P/S | ? | 66.6 | 78.0 | 57.5 | 46.4 | 56.1 | 40.3 | |||
| P/BV | ? | 1.22 | 1.63 | 1.56 | 1.53 | 2.22 | 1.59 | |||
| EV/EBITDA | ? | -0.66 | -1.40 | -1.14 | -1.38 | -2.87 | -1.68 | |||
| Debt/EBITDA | 1.83 | 1.73 | 1.56 | 1.81 | 1.36 | 1.36 | ||||
| R&D/CAPEX, % | 16 867% | 2 296 500% | 458.0% | 32 515% | 47 711% | 1 612% | ||||
| CAPEX/Revenue, % | 7.11% | 0.04% | 241.5% | 3.29% | 1.72% | 62.1% | ||||
| Agios Pharmaceuticals shareholders | ||||||||||
